GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » ROE % Adjusted to Book Value

AN2 Therapeutics (AN2 Therapeutics) ROE % Adjusted to Book Value : -10.48% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics ROE % Adjusted to Book Value?

AN2 Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -51.27%. AN2 Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 4.89. AN2 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -10.48%.

AN2 Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for AN2 Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AN2 Therapeutics ROE % Adjusted to Book Value Chart

AN2 Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -26.85 -12.03

AN2 Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.30 -29.70 -35.02 -17.14 -10.48

Competitive Comparison of AN2 Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, AN2 Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AN2 Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's ROE % Adjusted to Book Value falls into.


AN2 Therapeutics ROE % Adjusted to Book Value Calculation

AN2 Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-58.83% / 4.89
=-12.03%

AN2 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-51.27% / 4.89
=-10.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AN2 Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics (AN2 Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
LQDA ANAB LYEL TSHA GNLX DYN FDMT EWTX ALEC AVXL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027
Website
https://www.an2therapeutics.com
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Executives
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Kabeer Aziz director 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Adjuvant Global Health Technology Fund De, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Robin Shane Readnour director 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Kevin Michael Krause officer: Chief Strategy Officer 369 27TH STREET, SAN FRANCISCO CA 94131
Eric Easom director, officer: Chief Executive Officer 171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Joshua M Eizen officer: See Remarks 3023 MONTBRETIA WAY, SAN RAMON CA 94582
Margaret M Fitzpatrick director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Ra Capital Nexus Fund Ii, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Melvin K Spigelman director THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Sanjay Chanda officer: Chief Development Officer C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Adjuvant Global Health Technology Fund, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak officer: Chief Accounting Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Lucy Day officer: Chief Financial Officer 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301